Microbes that set up home in the gut may have an impact on mental health, according to a major study into wellbeing and the bacteria that live inside us.
Researchers in Belgium found that people with depression had consistently low levels of bacteria known as Coprococcus and Dialister whether they took antidepressants or not.
If the preliminary finding stands up to further scrutiny, it could pave the way for new treatments for mental health disorders based on probiotics that boost levels of “good” bacteria in the intestines.
4D Pharma plc (LON:DDDD) is a world leader in the development of live biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacteria, that is applicable to the prevention, treatment or cure of a disease.
